First IL-17A biologic approved for polymyalgia rheumatica - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

First IL-17A biologic approved for polymyalgia rheumatica

  • By

  • Mouj Hijazi

  • November 17, 2026

  • 2 min

Share

Clinical Scorecard: First IL-17A inhibitor approved for polymyalgia rheumatica

At a Glance

CategoryDetail
ConditionPolymyalgia rheumatica (PMR)
Key MechanismsSecukinumab is a monoclonal antibody that targets IL-17A, a cytokine involved in inflammatory signaling.
Target PopulationAdults with PMR who have had an inadequate response to corticosteroids or cannot tolerate corticosteroid tapering.
Care SettingTreatment of adults with PMR using secukinumab in combination with a glucocorticoid taper; secukinumab may be continued alone after glucocorticoids are discontinued.

Key Highlights

  • The FDA approved secukinumab 150 mg for adults with PMR who have an inadequate response to corticosteroids or cannot tolerate corticosteroid tapering.
  • In the 52-week REPLENISH trial, sustained remission occurred in 40.5% of patients receiving secukinumab 150 mg and 20.5% receiving placebo.
  • Mean adjusted cumulative glucocorticoid dose through week 52 was significantly lower with secukinumab than placebo (1,683.2 mg vs 2,093 mg).
  • Median time to initiation of rescue treatment for a PMR flare was 282 days with secukinumab and 157 days with placebo.
  • The prescribing information warns of serious infections and inflammatory bowel disease; a fatal case of cryptococcal meningitis occurred in a secukinumab-treated patient.

Guideline-Based Recommendations

Diagnosis

    Management

    • According to the prescribing information, the recommended dose is secukinumab 150 mg by subcutaneous injection at weeks 0, 1, 2, 3, and 4, followed by dosing every 4 weeks.
    • The prescribing information recommends use with a glucocorticoid taper; secukinumab may be continued alone after glucocorticoids are discontinued.
    • The prescribing information contraindicates secukinumab in patients with serious hypersensitivity to the drug or its excipients.

    Monitoring & Follow-up

    • The prescribing information advises evaluating patients for tuberculosis before treatment.
    • The prescribing information advises completing age-appropriate vaccinations before treatment.

    Risks

    • The prescribing information warns of serious infections and inflammatory bowel disease.
    • In REPLENISH, serious adverse events occurred in 15.9% of patients receiving secukinumab 150 mg and 14.2% receiving placebo.
    • Hypersensitivity reactions occurred in 14% of secukinumab-treated patients and 9% of placebo-treated patients; urinary tract infections occurred in 13% and 7%, respectively.
    • A fatal case of cryptococcal meningitis occurred in a secukinumab-treated patient.

    Patient & Prescribing Data

    Adults with PMR who have had an inadequate response to corticosteroids or cannot tolerate corticosteroid tapering; REPLENISH enrolled adults with at least one relapse while tapering glucocorticoids.

    The approved regimen is 150 mg subcutaneously at weeks 0, 1, 2, 3, and 4, then every 4 weeks, with a glucocorticoid taper. Secukinumab may be continued alone after glucocorticoids are discontinued.

    Clinical Best Practices

    • The prescribing information advises evaluating for tuberculosis and completing age-appropriate vaccinations before starting secukinumab.
    • The prescribing information warns of serious infections and inflammatory bowel disease.
    • The prescribing information specifies a loading schedule followed by dosing every 4 weeks, alongside a glucocorticoid taper.

    Related Resources & Content

    Original Source(s)

    Related Content